Cargando…
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little is known about them in thyroid cancer. We investigated the role of PD-L1 in thyroid cancer with respect to BRAF mutation and MAP kin...
Autores principales: | Brauner, Eran, Gunda, Viswanath, Borre, Pierre Vanden, Zurakowski, David, Kim, Yon Seon, Dennett, Kate Virginia, Amin, Salma, Freeman, Gordon James, Parangi, Sareh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941380/ https://www.ncbi.nlm.nih.gov/pubmed/26943572 http://dx.doi.org/10.18632/oncotarget.7839 |
Ejemplares similares
-
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer
por: Borre, Pierre Vanden, et al.
Publicado: (2014) -
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
por: Gunda, Viswanath, et al.
Publicado: (2018) -
The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010) -
Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
por: Xu, Zhen, et al.
Publicado: (2023) -
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways
por: Gunda, V, et al.
Publicado: (2014)